Cell Growth & Differentiation, Vol 6, Issue 9 1151-1161, Copyright © 1995 by American Association of Cancer Research

ARTICLES

Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines

E Kalkhoven, BA Roelen, JP de Winter, CL Mummery, AJ van den Eijnden-van Raaij, PT van der Saag and B van der Burg
Hubrecht Laboratory, Netherlands Institute for Developmental Biology, Utrecht, The Netherlands.

Loss of sensitivity to growth inhibition by transforming growth factor (TGF)-beta is a phenomenon often observed in human epithelial tumor cells and is linked to malignant progression. We tested a panel of estrogen receptor (ER)-positive and -negative breast cell lines for their sensitivity to TGF-beta and a related member of the TGF-beta superfamily, activin. Both TGF-beta-sensitive (MCF7, Hs578T, and BT20) and -resistant (two T47D variants, ZR75-1, MDA-MB231, and MDA-MB468) cell lines were found, with no strict correlation between ER content and sensitivity to TGF-beta. In contrast, all four ER-positive cell lines were inhibited by activin A, whereas the ER-negative lines were not. To examine whether resistance to TGF-beta and activin resulted from the absence of the corresponding receptors, mRNA expression of the types I and II receptors was studied. TGF-beta receptor II was not expressed in the two T47D variants and was low in ZR75-1 cells. Upon stable transfection of the TGF-beta receptor II in one of the T47D variants, sensitivity to TGF-beta 1 and TGF-beta 2 was restored with respect to inhibition of anchorage-dependent and -independent proliferation, indicating that other signal transduction components are functionally intact. Sensitivity to TGF-beta in the transfectants was dependent on the expression level of the newly introduced receptor. Resistance to activin in the ER-negative cell lines could be explained in BT20 and Hs578T cells, but not in MDA-MB231 and MDA-MB468, by low activin receptor expression. These results show that resistance to TGF-beta and activin is often, but not always, due to reduced expression of the signaling receptor in breast cancer cells. The activin resistance of ER-negative breast tumor cells may be involved in their increased malignancy compared with ER-positive cells.

This article has been cited by other articles:

				Y. Tang, Z. Liu, L. Zhao, T. L. Clemens, and X. Cao Smad7 Stabilizes {beta}-Catenin Binding to E-cadherin Complex and Promotes Cell-Cell Adhesion J. Biol. Chem., August 29, 2008; 283(35): 23956 - 23963. [Abstract] [Full Text] [PDF]

				S. Bharathy, W. Xie, J. M. Yingling, and M. Reiss Cancer-Associated Transforming Growth Factor {beta} Type II Receptor Gene Mutant Causes Activation of Bone Morphogenic Protein-Smads and Invasive Phenotype Cancer Res., March 15, 2008; 68(6): 1656 - 1666. [Abstract] [Full Text] [PDF]

				J. E Burdette and T. K Woodruff Activin and estrogen crosstalk regulates transcription in human breast cancer cells Endocr. Relat. Cancer, September 1, 2007; 14(3): 679 - 689. [Abstract] [Full Text] [PDF]

				D. Razanajaona, S. Joguet, A.-S. Ay, I. Treilleux, S. Goddard-Leon, L. Bartholin, and R. Rimokh Silencing of FLRG, an Antagonist of Activin, Inhibits Human Breast Tumor Cell Growth Cancer Res., August 1, 2007; 67(15): 7223 - 7229. [Abstract] [Full Text] [PDF]

				J. E. Burdette, J. S. Jeruss, S. J. Kurley, E. J. Lee, and T. K. Woodruff Activin A Mediates Growth Inhibition and Cell Cycle Arrest through Smads in Human Breast Cancer Cells Cancer Res., September 1, 2005; 65(17): 7968 - 7975. [Abstract] [Full Text] [PDF]

				A. Lacerte, E.-H. Lee, R. Reynaud, L. Canaff, C. de Guise, D. Devost, S. Ali, G. N. Hendy, and J.-J. Lebrun Activin Inhibits Pituitary Prolactin Expression and Cell Growth through Smads, Pit-1 and Menin Mol. Endocrinol., June 1, 2004; 18(6): 1558 - 1569. [Abstract] [Full Text] [PDF]

				M. B. Buck, P. Fritz, J. Dippon, G. Zugmaier, and C. Knabbe Prognostic Significance of Transforming Growth Factor {beta} Receptor II in Estrogen Receptor-Negative Breast Cancer Patients Clin. Cancer Res., January 15, 2004; 10(2): 491 - 498. [Abstract] [Full Text] [PDF]

				J. S. Jeruss, C. D. Sturgis, A. W. Rademaker, and T. K. Woodruff Down-Regulation of Activin, Activin Receptors, and Smads in High-Grade Breast Cancer Cancer Res., July 1, 2003; 63(13): 3783 - 3790. [Abstract] [Full Text] [PDF]

				L. Wu, Y. Wu, B. Gathings, M. Wan, X. Li, W. Grizzle, Z. Liu, C. Lu, Z. Mao, and X. Cao Smad4 as a Transcription Corepressor for Estrogen Receptor alpha J. Biol. Chem., April 18, 2003; 278(17): 15192 - 15200. [Abstract] [Full Text] [PDF]

				N. Dumont, A. V. Bakin, and C. L. Arteaga Autocrine Transforming Growth Factor-beta Signaling Mediates Smad-independent Motility in Human Cancer Cells J. Biol. Chem., January 24, 2003; 278(5): 3275 - 3285. [Abstract] [Full Text] [PDF]

				D. R. Mercatante, J. L. Mohler, and R. Kole Cellular Response to an Antisense-mediated Shift of Bcl-x Pre-mRNA Splicing and Antineoplastic Agents J. Biol. Chem., December 13, 2002; 277(51): 49374 - 49382. [Abstract] [Full Text] [PDF]

				L. Y. W. Bourguignon, P. A. Singleton, H. Zhu, and B. Zhou Hyaluronan Promotes Signaling Interaction between CD44 and the Transforming Growth Factor beta Receptor I in Metastatic Breast Tumor Cells J. Biol. Chem., October 11, 2002; 277(42): 39703 - 39712. [Abstract] [Full Text] [PDF]

				M. A. Engelse, J. H.P. Lardenoye, J. M. Neele, J. M. Grimbergen, M. R. de Vries, M. L.M. Lamfers, H. Pannekoek, P. H.A. Quax, and C. J.M. de Vries Adenoviral Activin A Expression Prevents Intimal Hyperplasia in Human and Murine Blood Vessels by Maintaining the Contractile Smooth Muscle Cell Phenotype Circ. Res., May 31, 2002; 90(10): 1128 - 1134. [Abstract] [Full Text] [PDF]

				J.-H. Kim, P. J. Wilder, J. Hou, T. Nowling, and A. Rizzino Activation of the Murine Type II Transforming Growth Factor-beta Receptor Gene. UP-REGULATION AND FUNCTION OF THE TRANSCRIPTION FACTOR Elf-3/Ert/Esx/Ese-1 J. Biol. Chem., May 10, 2002; 277(20): 17520 - 17530. [Abstract] [Full Text] [PDF]

				F. M. Reis, L. Cobellis, L. C. Tameirao, G. Anania, S. Luisi, I. S. B. Silva, W. Gioffre, A. M. di Blasio, and F. Petraglia Serum and Tissue Expression of Activin A in Postmenopausal Women with Breast Cancer J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2277 - 2282. [Abstract] [Full Text] [PDF]

				S. Fanayan, S. M. Firth, and R. C. Baxter Signaling through the Smad Pathway by Insulin-like Growth Factor-binding Protein-3 in Breast Cancer Cells. RELATIONSHIP TO TRANSFORMING GROWTH FACTOR-beta 1 SIGNALING J. Biol. Chem., February 22, 2002; 277(9): 7255 - 7261. [Abstract] [Full Text] [PDF]

				W. Xie, J. C. Mertens, D. J. Reiss, D. L. Rimm, R. L. Camp, B. G. Haffty, and M. Reiss Alterations of Smad Signaling in Human Breast Carcinoma Are Associated with Poor Outcome: A Tissue Microarray Study Cancer Res., January 1, 2002; 62(2): 497 - 505. [Abstract] [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				S Wildi, J Kleeff, H Maruyama, C A Maurer, M W Buchler, and M Korc Overexpression of activin A in stage IV colorectal cancer Gut, September 1, 2001; 49(3): 409 - 417. [Abstract] [Full Text] [PDF]

				N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text]

				A Franchi, O Gallo, I Sardi, and M Santucci Downregulation of transforming growth factor {beta} type II receptor in laryngeal carcinogenesis J. Clin. Pathol., March 1, 2001; 54(3): 201 - 204. [Abstract] [Full Text] [PDF]

				Y. Zhou, H. Sun, D. C. Danila, S. R. Johnson, D. P. Sigai, X. Zhang, and A. Klibanski Truncated Activin Type I Receptor Alk4 Isoforms Are Dominant Negative Receptors Inhibiting Activin Signaling Mol. Endocrinol., December 1, 2000; 14(12): 2066 - 2075. [Abstract] [Full Text]

				A. H. Charpentier, A. K. Bednarek, R. L. Daniel, K. A. Hawkins, K. J. Laflin, S. Gaddis, M. C. MacLeod, and C. M. Aldaz Effects of Estrogen on Global Gene Expression: Identification of Novel Targets of Estrogen Action Cancer Res., November 1, 2000; 60(21): 5977 - 5983. [Abstract] [Full Text]

				M. Guo and J. J. Reiners Jr Phorbol ester-induced production of cytostatic factors by normal and oncogenic Ha-ras-transformed human breast cell lines Carcinogenesis, July 1, 2000; 21(7): 1303 - 1312. [Abstract] [Full Text] [PDF]

				Y. Liu, X. Zhong, W. Li, M. G. Brattain, and S. S. Banerji The Role of Sp1 in the Differential Expression of Transforming Growth Factor-beta Receptor Type II in Human Breast Adenocarcinoma MCF-7 Cells J. Biol. Chem., April 14, 2000; 275(16): 12231 - 12236. [Abstract] [Full Text] [PDF]

				J. N. Rich, M. Zhang, M. B. Datto, D. D. Bigner, and X.-F. Wang Transforming Growth Factor-beta -mediated p15INK4B Induction and Growth Inhibition in Astrocytes Is SMAD3-dependent and a Pathway Prominently Altered in Human Glioma Cell Lines J. Biol. Chem., December 3, 1999; 274(49): 35053 - 35058. [Abstract] [Full Text] [PDF]

				M. A. Sovak, M. Arsura, G. Zanieski, K. T. Kavanagh, and G. E. Sonenshein The Inhibitory Effects of Transforming Growth Factor {beta}1 on Breast Cancer Cell Proliferation Are Mediated through Regulation of Aberrant Nuclear Factor-{{kappa}}B/Rel Expression Cell Growth Differ., August 1, 1999; 10(8): 537 - 544. [Abstract] [Full Text]

				R. Anbazhagan, D. M. Bornman, J. C. Johnston, W. H. Westra, and E. Gabrielson The S387Y Mutation of the Transforming Growth Factor-{beta} Receptor Type I Gene Is Uncommon in Metastases of Breast Cancer and Other Common Types of Adenocarcinoma Cancer Res., July 1, 1999; 59(14): 3363 - 3364. [Abstract] [Full Text] [PDF]

				H.-J. Zhu and A. M. Sizeland A Pivotal Role for the Transmembrane Domain in Transforming Growth Factor-{beta} Receptor Activation J. Biol. Chem., April 23, 1999; 274(17): 11773 - 11781. [Abstract] [Full Text] [PDF]

				C. Wong, E. M. Rougier-Chapman, J. P. Frederick, M. B. Datto, N. T. Liberati, J.-M. Li, and X.-F. Wang Smad3-Smad4 and AP-1 Complexes Synergize in Transcriptional Activation of the c-Jun Promoter by Transforming Growth Factor beta Mol. Cell. Biol., March 1, 1999; 19(3): 1821 - 1830. [Abstract] [Full Text] [PDF]

				S. Ammanamanchi, S.-J. Kim, L.-Z. Sun, and M. G. Brattain Induction of Transforming Growth Factor-beta Receptor Type II Expression in Estrogen Receptor-positive Breast Cancer Cells through SP1 Activation by 5-Aza-2'-deoxycytidine J. Biol. Chem., June 26, 1998; 273(26): 16527 - 16534. [Abstract] [Full Text] [PDF]

				P. P.-c. Hu, M. B. Datto, and X.-f. Wang Molecular Mechanisms of Transforming Growth Factor-{beta} Signaling Endocr. Rev., June 1, 1998; 19(3): 349 - 363. [Abstract] [Full Text]

				G. Wu, R. S. Fan, W. Li, V. Srinivas, and M. G. Brattain Regulation of Transforming Growth Factor-beta Type II Receptor Expression in Human Breast Cancer MCF-7 Cells by Vitamin D3 and Its Analogues J. Biol. Chem., March 27, 1998; 273(13): 7749 - 7756. [Abstract] [Full Text] [PDF]

				L. Sun and C. Chen Expression of Transforming Growth Factor beta  Type III Receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells J. Biol. Chem., October 3, 1997; 272(40): 25367 - 25372. [Abstract] [Full Text] [PDF]

				C. Chen, X.-F. Wang, and L. Sun Expression of Transforming Growth Factor beta  (TGFbeta ) Type III Receptor Restores Autocrine TGFbeta 1 Activity in Human Breast Cancer MCF-7 Cells J. Biol. Chem., May 9, 1997; 272(19): 12862 - 12867. [Abstract] [Full Text] [PDF]

				K. M. Koli, T. T. Ramsey, Y. Ko, T. C. Dugger, M. G. Brattain, and C. L. Arteaga Blockade of Transforming Growth Factor-beta Signaling Does Not Abrogate Antiestrogen-induced Growth Inhibition of Human Breast Carcinoma Cells J. Biol. Chem., March 28, 1997; 272(13): 8296 - 8302. [Abstract] [Full Text] [PDF]

				K. M. Koli and C. L. Arteaga Processing of the Transforming Growth Factor beta Type I and II Receptors. BIOSYNTHESIS AND LIGAND-INDUCED REGULATION J. Biol. Chem., March 7, 1997; 272(10): 6423 - 6427. [Abstract] [Full Text] [PDF]

				S. Ammanamanchi and M. G. Brattain Sp3 Is a Transcriptional Repressor of Transforming Growth Factor-beta Receptors J. Biol. Chem., January 26, 2001; 276(5): 3348 - 3352. [Abstract] [Full Text] [PDF]

				D. L. Segev, T. U. Ha, T. T. Tran, M. Kenneally, P. Harkin, M. Jung, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFkappa B-mediated Pathway J. Biol. Chem., September 8, 2000; 275(37): 28371 - 28379. [Abstract] [Full Text] [PDF]

				S. Fanayan, S. M. Firth, A. J. Butt, and R. C. Baxter Growth Inhibition by Insulin-like Growth Factor-binding Protein-3 in T47D Breast Cancer Cells Requires Transforming Growth Factor-beta (TGF-beta ) and the Type II TGF-beta Receptor J. Biol. Chem., December 8, 2000; 275(50): 39146 - 39151. [Abstract] [Full Text] [PDF]

				S. Ammanamanchi and M. G. Brattain 5-AzaC Treatment Enhances Expression of Transforming Growth Factor-beta Receptors through Down-regulation of Sp3 J. Biol. Chem., August 24, 2001; 276(35): 32854 - 32859. [Abstract] [Full Text] [PDF]